The genetic basis of hepatosplenic T-cell lymphoma

Cancer Discovery

Volumn 7, Issue 4, 2017, Pages 369-379

  McKinney, Matthew ^a   Moffitt, Andrea B ^b   Gaulard, Philippe ^c   Travert, Marion ^c   Leval, Laurence De ^d   Raffeld, Alina Nicolae Mark ^e   Jaffe, Elaine S ^e   Pittaluga, Stefania ^e   Xi, Liqiang ^e   Heavican, Tayla ^f   Iqbal, Javeed ^f   Belhadj, Karim ^c   Delfau Larue, Marie Helene ^c   Fataccioli, Virginie ^c   Czader, Magdalena B ^g   Lossos, Izidore S ^h   Chapman Fredricks, Jennifer R ^h   Richards, Kristy L ⁱ   Fedoriw, Yuri ⁱ   Ondrejka, Sarah L ^j   Hsi, Eric D ^j   Low, Lawrence ^k   Weisenburger, Dennis ^k   Chan, Wing C ^k   Mehta Shah, Neha ^l   Horwitz, Steven ^l   Bernal Mizrachi, Leon ^m   Flowers, Christopher R ^m   Beaven, Anne W ^a   Parihar, Mayur ⁿ   Baseggio, Lucile ^o   Parrens, Marie ^p   Moreau, Anne ^q   Sujobert, Pierre ^r   Pilichowska, Monika ^s   Evens, Andrew M ^s   Chadburn, Amy ^t   Au Yeung, Rex K H ^u   Srivastava, Gopesh ^u   Choi, William W L ^u   Goodlad, John R ^v   Aurer, Igor ^w   Basic Kinda, Sandra ^w   Gascoyne, Randy D ^x   Davis, Nicholas S ^a   Li, Guojie ^a   Zhang, Jenny ^a   Rajagopalan, Deepthi ^a   Reddy, Anupama ^a   Love, Cassandra ^a   Levy, Shawn ^y   Zhuang, Yuan ^a   Datta, Jyotishka ^z   Dunson, David B ^z   Davé, Sandeep S ^a,b   more..

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY   (United States)

^c UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^d LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^e NATIONAL CANCER INSTITUTE   (United States)

^f UNIVERSITY OF NEBRASKA AT OMAHA   (United States)

^g INDIANA UNIVERSITY   (United States)

^h UNIVERSITY OF MIAMI   (United States)

ⁱ UNIVERSITY OF NORTH CAROLINA   (United States)

^j LERNER RESEARCH INSTITUTE   (United States)

^k CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^l MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^m EMORY UNIVERSITY   (United States)

ⁿ Tata Medical Centre   (India)

^o CENTRE HOSPITALIER LYON SUD   (France)

^p Hôpital Pessac   (France)

^q HÔTEL DIEU   (France)

^r UNIVERSITÉ LYON 1   (France)

^s TUFTS MEDICAL CENTER   (United States)

^t Department of Obstetrics Gynecology   (United States)

^u UNIVERSITY OF HONG KONG   (Hong Kong)

^v WESTERN GENERAL HOSPITAL   (United Kingdom)

^w KBC Zagreb   (Croatia)

^x UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^y HUDSONALPHA INSTITUTE FOR BIOTECHNOLOGY   (United States)

^z Duke University   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

IDELALISIB; LACTATE DEHYDROGENASE; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; SELUMETINIB; STAT5B PROTEIN; ARID1B PROTEIN, HUMAN; DNA BINDING PROTEIN; DNA HELICASE; EZH2 PROTEIN, HUMAN; HISTONE LYSINE METHYLTRANSFERASE; INO80 PROTEIN, HUMAN; KRAS PROTEIN, HUMAN; PROTEIN P21; PROTEIN P53; SET2 PROTEIN, HUMAN; TP53 PROTEIN, HUMAN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR EZH2; TUMOR SUPPRESSOR PROTEIN;

ADOLESCENT; ADULT; ARTICLE; B CELL LYMPHOMA; BIOINFORMATICS; CELL PROLIFERATION; CELL SURVIVAL; CHILD; CHROMOSOME ABERRATION; CLINICAL ARTICLE; COLONY FORMING UNIT; CONTROLLED STUDY; COPY NUMBER VARIATION; ELECTROCORTICOGRAPHY; FEMALE; GENE FUNCTION; GENE MAPPING; GENE MUTATION; GENE OVEREXPRESSION; GENE SILENCING; GENETIC DIFFERENCE; GENETIC TRANSFECTION; HEPATOSPLENIC T CELL LYMPHOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER DISEASE; MALE; MTT ASSAY; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SPLEEN DISEASE; T CELL LYMPHOMA; TREATMENT RESPONSE; WESTERN BLOTTING; WHOLE EXOME SEQUENCING; AGED; COMPLICATION; EXOME; GENETICS; LIVER TUMOR; MIDDLE AGED; NUCLEOTIDE SEQUENCE; PATHOLOGY; PRESCHOOL CHILD; SPLEEN TUMOR; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BASE SEQUENCE; CHILD; CHILD, PRESCHOOL; DNA HELICASES; DNA-BINDING PROTEINS; ENHANCER OF ZESTE HOMOLOG 2 PROTEIN; EXOME; FEMALE; HISTONE-LYSINE N-METHYLTRANSFERASE; HUMANS; LIVER NEOPLASMS; LYMPHOMA, T-CELL; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS P21(RAS); SPLENIC NEOPLASMS; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS; YOUNG ADULT;

EID: 85017152143     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-16-0330     Document Type: Article

References (47)

1. γδ T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients. Blood 2003;102:4261–9.
2. Weisenburger DD, Savage KJ, Harris NL, Gascoyne RD, Jaffe ES, MacLennan KA, et al. Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project. Blood 2011;117:3402–8.
3. Alonsozana E, Stamberg J, Kumar D, Jaffe E, Medeiros L, Frantz C, et al. Isochromosome 7q: the primary cytogenetic abnormality in hepatosplenic T cell lymphoma. Leukemia 1997;11:1367–72.
4. Wlodarska I, Martin-Garcia N, Achten R, De Wolf-Peeters C, Pauwels P, Tulliez M, et al. Fluorescence in situ hybridization study of chromosome 7 aberrations in hepatosplenic T-cell lymphoma: isochromosome 7q as a common abnormality accumulating in forms with features of cytologic progression. Genes Chromosomes Cancer 2002;33: 243–51.
5. Finalet Ferreiro J, Rouhigharabaei L, Urbankova H, van der Krogt JA, Michaux L, Shetty S, et al. Integrative genomic and transcriptomic analysis identified candidate genes implicated in the pathogenesis of hepatosplenic T-cell lymphoma. PloS ONE 2014;9:e102977.
6. Travert M, Huang Y, de Leval L, Martin-Garcia N, Delfau-Larue MH, Berger F, et al. Molecular features of hepatosplenic T-cell lymphoma unravels potential novel therapeutic targets. Blood 2012;119: 5795–806.
7. Cools J. RHOA mutations in peripheral T cell lymphoma. Nat Genet 2014;46:320–1.
8. Palomero T, Couronné L, Khiabanian H, Kim M-Y, Ambesi-Impiombato A, Perez-Garcia A, et al. Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas. Nat Genet 2014;46:166–70.
9. Sakata-Yanagimoto M, Enami T, Yoshida K, Shiraishi Y, Ishii R, Miyake Y, et al. Somatic RHOA mutation in angioimmunoblastic T cell lymphoma. Nat Genet 2014;46:171–5.
10. Jiang L, Gu ZH, Yan ZX, Zhao X, Xie YY, Zhang ZG, et al. Exome sequencing identifies somatic mutations of DDX3X in natural killer/ T-cell lymphoma. Nat Genet 2015;47:1061–6.
11. Odejide O, Weigert O, Lane AA, Toscano D, Lunning MA, Kopp N, et al. A targeted mutational landscape of angioimmunoblastic T-cell lymphoma. Blood 2014;123:1293–6.
12. Yoo HY, Sung MK, Lee SH, Kim S, Lee H, Park S, et al. A recurrent inactivating mutation in RHOA GTPase in angioimmunoblastic T cell lymphoma. Nat Genet 2014;46:371–5.
13. Choi J, Goh G, Walradt T, Hong BS, Bunick CG, Chen K, et al. Genomic landscape of cutaneous T cell lymphoma. Nat Genet 2015;47:1011–9.
14. Crescenzo R, Abate F, Lasorsa E, Gaudiano M, Chiesa N, Di Giacomo F, et al. Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma. Cancer Cell 2015;27:516–32.
15. Kataoka K, Nagata Y, Kitanaka A, Shiraishi Y, Shimamura T, Yasunaga J-i, et al. Integrated molecular analysis of adult T cell leukemia/ lymphoma. Nat Genet 2015;47:1304–15.
16. Ungewickell A, Bhaduri A, Rios E, Reuter J, Lee CS, Mah A, et al. Genomic analysis of mycosis fungoides and Sezary syndrome identifies recurrent alterations in TNFR2. Nat Genet 2015;47:1056–60.
17. Wang L, Ni X, Covington KR, Yang BY, Shiu J, Zhang X, et al. Genomic profiling of Sezary syndrome identifies alterations of key T cell signaling and differentiation genes. Nat Genet 2015;47:1426–34.
18. da Silva Almeida A, Abate F, Khiabanian H, Martinez-Escala E, Guitart J, Tensen C, et al. The mutational landscape of cutaneous T cell lymphoma and Sezary syndrome. Nat Genet 2015;47:1465–70.
19. Küçük C, Jiang B, Hu X, Zhang W, Chan JKC, Xiao W, et al. Activating mutations of STAT5B and STAT3 in lymphomas derived from γδ-T or NK cells. Nat Commun 2015;6:6025.
20. γδ hepatosplenic T-cell lymphomas. Leukemia 2014;28:2244–8.
21. Love C, Sun Z, Jima D, Li G, Zhang J, Miles R, et al. The genetic landscape of mutations in Burkitt lymphoma. Nat Genet 2012;44:1321–5.
22. Zhang J, Jima D, Moffitt AB, Liu Q, Czader M, Hsi ED, et al. The genomic landscape of mantle cell lymphoma is related to the epigenet-ically determined chromatin state of normal B cells. Blood 2014;123: 2988–96.
23. Zhang J, Grubor V, Love CL, Banerjee A, Richards KL, Mieczkowski PA, et al. Genetic heterogeneity of diffuse large B-cell lymphoma. Proc Natl Acad Sci 2013;110:1398–403.
24. +. Leukemia 2001;15:1641–9.
25. Morin RD, Mendez-Lago M, Mungall AJ, Goya R, Mungall KL, Corbett RD, et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 2011;476:298–303.
26. Lohr JG, Stojanov P, Lawrence MS, Auclair D, Chapuy B, Sougnez C, et al. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci U S A 2012;109:3879–84.
27. Schmitz R, Young RM, Ceribelli M, Jhavar S, Xiao W, Zhang M, et al. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature 2012;490:116–20.
28. Richter J, Schlesner M, Hoffmann S, Kreuz M, Leich E, Burkhardt B, et al. Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing. Nat Genet 2012;44:1316–20.
29. Beà S, Valdés-Mas R, Navarro A, Salaverria I, Martín-Garcia D, Jares P, et al. Landscape of somatic mutations and clonal evolution in mantle cell lymphoma. Proc Natl Acad Sci 2013;110:18250–5.
30. Meissner B, Kridel R, Lim RS, Rogic S, Tse K, Scott DW, et al. The E3 ubiquitin ligase UBR5 is recurrently mutated in mantle cell lymphoma. Blood 2013;121:3161–4.
31. Rebehmed J, Revy P, Faure G, de Villartay JP, Callebaut I. Expanding the SRI domain family: a common scaffold for binding the phospho-rylated C-terminal domain of RNA polymerase II. FEBS Lett 2014;588: 4431–7.
32. Edmunds JW, Mahadevan LC, Clayton AL. Dynamic histone H3 methylation during gene induction: HYPB/Setd2 mediates all H3K36 trimethylation. EMBO J 2008;27:406–20.
33. Xie P, Tian C, An L, Nie J, Lu K, Xing G, et al. Histone methyltransferase protein SETD2 interacts with p53 and selectively regulates its downstream genes. Cell Signal 2008;20:1671–8.
34. Yoh SM, Lucas JS, Jones KA. The Iws1:Spt6:CTD complex controls cotranscriptional mRNA biosynthesis and HYPB/Setd2-mediated histone H3K36 methylation. Genes Dev 2008;22:3422–34.
35. Li F, Mao G, Tong D, Huang J, Gu L, Yang W, et al. The histone mark H3K36me3 regulates human DNA mismatch repair through its interaction with MutSalpha. Cell 2013;153:590–600.
36. Carvalho S, Vitor AC, Sridhara SC, Martins FB, Raposo AC, Des-terro JM, et al. SETD2 is required for DNA double-strand break repair and activation of the p53-mediated checkpoint. eLife 2014;3: e02482.
37. Pfister SX, Ahrabi S, Zalmas LP, Sarkar S, Aymard F, Bachrati CZ, et al. SETD2-dependent histone H3K36 trimethylation is required for homologous recombination repair and genome stability. Cell Rep 2014;7:2006–18.
38. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005;102:15545–50.
39. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004;304:554.
40. Farcet JP, Gaulard P, Marolleau JP, Le Couedic JP, Henni T, Gourdin MF, et al. Hepatosplenic T-cell lymphoma: sinusal/sinusoidal localization of malignant cells expressing the T-cell receptor gamma delta. Blood 1990;75:2213–9.
41. Mackey AC, Green L, Liang LC, Dinndorf P, Avigan M. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007;44:265–7.
42. Dalgliesh GL, Furge K, Greenman C, Chen L, Bignell G, Butler A, et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 2010;463:360–3.
43. Zhu X, He F, Zeng H, Ling S, Chen A, Wang Y, et al. Identification of functional cooperative mutations of SETD2 in human acute leukemia. Nat Genet 2014;46:287–93.
44. Jima DD, Zhang J, Jacobs C, Richards KL, Dunphy CH, Choi WW, et al. Deep sequencing of the small RNA transcriptome of normal and malignant human B cells identifies hundreds of novel microRNAs. Blood 2010;116:e118–27.
45. de Leval L, Parrens M, Le Bras F, Jais J-P, Fataccioli V, Martin A, et al. Angioimmunoblastic T-cell lymphoma is the most common T-cell lymphoma in two distinct French information data sets. Haemato-logica 2015;100:e361–e4.
46. Stewart SA, Dykxhoorn DM, Palliser D, Mizuno H, Yu EY, An DS, et al. Lentivirus-delivered stable gene silencing by RNAi in primary cells. RNA (New York, NY) 2003;9:493–501.
47. Walsh K, McKinney MS, Love C, Liu Q, Fan A, Patel A, et al. PAK1 mediates resistance to PI3K inhibition in lymphomas. Clin Cancer Res 2013;19:1106–15.